NCT00067743

A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)

A Multicenter, Open-Label Study to Evaluate the Preliminary Safety and Efficacy of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Celgene Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, open-label study in adult subjects with Type 1 Complex Regional Pain Syndrome. Subjects diagnosed with unilateral Type 1 CRPS will be enrolled sequentially to receive CC-5013 10 mg/day orally. For each subject the study consists of two phases: Pre-treatment phase(1 wk) and treatment phase (12 wks)

Detailed description

Once the subject completes the 12 week treatment phase the subject is eligible to continue on the trial. Subjects may continue until no further benefit is obtained.

Conditions

• Complex Regional Pain Syndrome (RSD)

Interventions

Type	Name	Description
DRUG	Lenalidomide	supplied as 5 mg capsules. Dosing as directed by physician but to start at 10 mg per day

Timeline

• Start date: 2003-08-01
• Primary completion: 2004-10-01
• Completion: 2007-08-01
• First posted: 2003-08-27
• Last updated: 2008-01-03

Locations

6 sites across 1 country: United States